Shattuck Labs (NASDAQ:STTK) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen has upgraded Shattuck Labs (NASDAQ:STTK) to a "hold" rating following analysts' reports on the stock.
• Shattuck Labs' recent performance shows a market capitalization of $74.25 million and a one-year stock range of $0.69 to $3.95.
• Insider buying activity includes Director Mona Ashiya purchasing over 6 million shares at an average price of $0.87, significantly increasing her ownership stake.

Shattuck Labs (NASDAQ:STTK - Get Free Report) was upgraded by stock analysts at Wall Street Zen to a "hold" rating in a research note issued to investors on Friday.

Several other research analysts have also recently weighed in on STTK. Leerink Partners decreased their target price on Shattuck Labs from $4.00 to $2.00 and set an "outperform" rating for the company in a research note on Thursday, August 14th. Needham & Company LLC reissued a "hold" rating on shares of Shattuck Labs in a report on Thursday, August 14th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $4.00.

Shattuck Labs Price Performance

Shares of NASDAQ STTK traded up $0.23 during mid-day trading on Friday, reaching $1.98. 526,991 shares of the company traded hands, compared to its average volume of 1,613,448. Shattuck Labs has a fifty-two week low of $0.69 and a fifty-two week high of $3.95. The firm has a market cap of $94.84 million, a PE ratio of -1.64 and a beta of 1.64. The stock has a fifty day simple moving average of $0.98 and a 200-day simple moving average of $1.01.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.01. As a group, analysts predict that Shattuck Labs will post -1.48 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Orbimed Advisors Llc purchased 6,306,127 shares of the firm's stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average price of $0.87 per share, for a total transaction of $5,486,330.49. Following the transaction, the director directly owned 5,255,106 shares of the company's stock, valued at $4,571,942.22. This trade represents a -600.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Mona Ashiya purchased 6,306,127 shares of the company's stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average cost of $0.87 per share, for a total transaction of $5,486,330.49. Following the purchase, the director directly owned 5,255,106 shares in the company, valued at $4,571,942.22. This represents a -600.00% increase in their position. The disclosure for this purchase can be found here. Company insiders own 12.00% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Bridgeway Capital Management LLC increased its position in shares of Shattuck Labs by 147.5% in the second quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company's stock worth $73,000 after acquiring an additional 55,000 shares in the last quarter. 683 Capital Management LLC increased its position in shares of Shattuck Labs by 4.3% in the second quarter. 683 Capital Management LLC now owns 1,095,000 shares of the company's stock worth $867,000 after acquiring an additional 45,000 shares in the last quarter. Jane Street Group LLC increased its position in shares of Shattuck Labs by 2,510.8% in the second quarter. Jane Street Group LLC now owns 289,671 shares of the company's stock worth $229,000 after acquiring an additional 278,576 shares in the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Shattuck Labs in the second quarter worth approximately $44,000. Finally, Pinnacle Associates Ltd. increased its position in shares of Shattuck Labs by 4.9% in the second quarter. Pinnacle Associates Ltd. now owns 1,363,723 shares of the company's stock worth $1,080,000 after acquiring an additional 64,000 shares in the last quarter. 58.74% of the stock is owned by hedge funds and other institutional investors.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.